Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02612779 · ClinicalTrials.gov registry record · Phase 2
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT02612779 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 74 participants.
The verdict
NCT02612779, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
Study of elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd Cohort) and elotuzumab in combination with nivolumab (EN Cohort) to assess the safety and efficacy of these combination therapies for treatment of relapsed or refractory MM patients.
Interventions
- DRUG Nivolumab
- DRUG Dexamethasone
- DRUG Pomalidomide
- DRUG Elotuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2016-02-09 |
| Est. Completion | 2020-06-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02612779
The ClinicalTrials.gov registry entry for NCT02612779 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Nivolumab is the first listed.
NCT02612779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02612779 about?
NCT02612779 is a clinical study titled "A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.". Study of elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd Cohort) and elotuzumab in combination with nivolumab (EN Cohort) to assess the safety and efficacy of these combination therapies for treatment of relapsed or refractory MM patients.
What is the current status of trial NCT02612779?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2016-02-09. Estimated completion is 2020-06-12.
What interventions are being tested in trial NCT02612779?
The interventions under investigation include: Nivolumab (DRUG), Dexamethasone (DRUG), Pomalidomide (DRUG), Elotuzumab (DRUG).
Who is sponsoring clinical trial NCT02612779?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.